Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HRMY NASDAQ:IMVT NASDAQ:KYMR NASDAQ:LNTH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHRMYHarmony Biosciences$32.20-2.3%$30.16$25.52▼$40.87$1.91B0.96705,861 shs461,366 shsIMVTImmunovant$31.11-4.8%$28.50$14.32▼$36.28$6.71B0.762.56 million shs864,698 shsKYMRKymera Therapeutics$74.13-0.6%$83.01$36.65▼$103.00$6.14B2.02494,538 shs639,437 shsLNTHLantheus$100.98-1.8%$88.01$47.25▼$104.00$6.69B-0.031.10 million shs746,238 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHRMYHarmony Biosciences+2.79%+4.67%+1.92%+16.34%-6.26%IMVTImmunovant+4.88%-2.48%+17.35%+22.54%+112.97%KYMRKymera Therapeutics+1.96%-8.41%-9.79%-10.64%+68.57%LNTHLantheus+2.56%+3.21%+19.81%+41.70%+29.12%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHRMYHarmony Biosciences$32.20-2.3%$30.16$25.52▼$40.87$1.91B0.96705,861 shs461,366 shsIMVTImmunovant$31.11-4.8%$28.50$14.32▼$36.28$6.71B0.762.56 million shs864,698 shsKYMRKymera Therapeutics$74.13-0.6%$83.01$36.65▼$103.00$6.14B2.02494,538 shs639,437 shsLNTHLantheus$100.98-1.8%$88.01$47.25▼$104.00$6.69B-0.031.10 million shs746,238 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHRMYHarmony Biosciences+2.79%+4.67%+1.92%+16.34%-6.26%IMVTImmunovant+4.88%-2.48%+17.35%+22.54%+112.97%KYMRKymera Therapeutics+1.96%-8.41%-9.79%-10.64%+68.57%LNTHLantheus+2.56%+3.21%+19.81%+41.70%+29.12%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHRMYHarmony Biosciences 2.27Hold$40.8926.98% UpsideIMVTImmunovant 2.45Hold$37.3320.00% UpsideKYMRKymera Therapeutics 2.95Moderate Buy$118.1059.31% UpsideLNTHLantheus 2.73Moderate Buy$101.860.87% UpsideCurrent Analyst Ratings BreakdownLatest HRMY, IMVT, KYMR, and LNTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2026LNTHLantheus MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$100.00 ➝ $115.005/26/2026LNTHLantheus Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)5/26/2026IMVTImmunovant GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$44.00 ➝ $62.005/22/2026HRMYHarmony Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/22/2026IMVTImmunovant Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$23.00 ➝ $30.005/21/2026IMVTImmunovant CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/21/2026IMVTImmunovant HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$35.00 ➝ $40.005/21/2026IMVTImmunovant Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$32.00 ➝ $43.005/11/2026LNTHLantheus Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$98.00 ➝ $115.005/8/2026LNTHLantheus CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/8/2026HRMYHarmony Biosciences Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$25.00 ➝ $29.00(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHRMYHarmony Biosciences$899.11M2.07$3.19 per share10.10$15.11 per share2.13IMVTImmunovantN/AN/AN/AN/A$4.19 per shareN/AKYMRKymera Therapeutics$51.48M118.46N/AN/A$19.42 per share3.82LNTHLantheus$1.55B4.25$6.43 per share15.70$16.43 per share6.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHRMYHarmony Biosciences$158.69M$2.4812.988.850.2216.20%17.19%11.99%8/4/2026 (Estimated)IMVTImmunovant-$505.61M-$2.78N/AN/AN/AN/A-65.66%-59.88%8/10/2026 (Estimated)KYMRKymera Therapeutics-$311.35M-$3.57N/AN/AN/A-611.94%-24.71%-22.05%8/10/2026 (Estimated)LNTHLantheus$233.56M$4.1524.3318.80N/A18.05%29.32%15.00%8/5/2026 (Estimated)Latest HRMY, IMVT, KYMR, and LNTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q4 2026IMVTImmunovant-$0.60-$0.73-$0.13-$0.73N/AN/A5/7/2026Q1 2026HRMYHarmony Biosciences$0.76$0.55-$0.21$0.55$220.84 million$215.39 million5/7/2026Q1 2026LNTHLantheus$1.25$1.46+$0.21$1.80$354.48 million$377.33 million4/30/2026Q1 2026KYMRKymera Therapeutics-$0.89-$0.71+$0.18-$0.71$8.27 million$34.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthHRMYHarmony BiosciencesN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/AKYMRKymera TherapeuticsN/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHRMYHarmony Biosciences0.153.583.56IMVTImmunovantN/A9.099.09KYMRKymera TherapeuticsN/A10.8110.81LNTHLantheus0.472.832.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHRMYHarmony Biosciences86.23%IMVTImmunovant47.08%KYMRKymera TherapeuticsN/ALNTHLantheus99.06%Insider OwnershipCompanyInsider OwnershipHRMYHarmony Biosciences11.00%IMVTImmunovant1.80%KYMRKymera Therapeutics15.98%LNTHLantheus1.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHRMYHarmony Biosciences20057.89 million51.53 millionOptionableIMVTImmunovant120205.31 million201.61 millionOptionableKYMRKymera Therapeutics17082.26 million69.11 millionOptionableLNTHLantheus1,19365.11 million64.00 millionOptionableHRMY, IMVT, KYMR, and LNTH HeadlinesRecent News About These CompaniesAssessing Lantheus Holdings (LNTH) Valuation After Strong Multi Month Share Price GainsJune 5 at 5:14 PM | finance.yahoo.comLantheus to Present at the Goldman Sachs 47th Annual Global Healthcare ConferenceJune 3 at 8:30 AM | globenewswire.comLantheus' LNTH-2513 (18F-GP1) PET/CT Awarded SNMMI’s Image of the YearJune 2 at 3:44 PM | markets.businessinsider.comLantheus' LNTH-2513 (18F-GP1) PET/CT Awarded SNMMI's Image of the YearJune 2 at 8:00 AM | globenewswire.comLantheus Holdings, Inc. (NASDAQ:LNTH) Receives Average Recommendation of "Moderate Buy" from AnalystsMay 29, 2026 | americanbankingnews.comAnalysts Are Bullish on Top Healthcare Stocks: IQVIA Holdings (IQV), Lantheus (LNTH)May 27, 2026 | theglobeandmail.comLantheus to Present at the William Blair 46th Annual Growth Stock ConferenceMay 27, 2026 | globenewswire.comLantheus Holdings gains after report it's evaluating a sale after offerMay 23, 2026 | msn.comHow The Story On Lantheus Holdings (LNTH) Is Shifting With PYLARIFY And Pipeline ExpectationsMay 23, 2026 | finance.yahoo.comLantheus weighs potential $7 billion sale, Bloomberg News reportsMay 22, 2026 | reuters.comLantheus Highlights New Radiodiagnostic Data at the 2026 SNMMI Annual MeetingMay 21, 2026 | globenewswire.comLantheus Announces Presentation of Data at the 2026 American Society of Clinical Oncology ...May 19, 2026 | caledonianrecord.comCLantheus Announces Presentation of Data at the 2026 American Society of Clinical Oncology (ASCO) Annual MeetingMay 19, 2026 | globenewswire.comWe Think You Should Be Aware Of Some Concerning Factors In Lantheus Holdings' (NASDAQ:LNTH) EarningsMay 15, 2026 | finance.yahoo.comLantheus Holdings (LNTH) price target increased by 10.39% to 103.33May 15, 2026 | msn.comLantheus Holdings, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 15, 2026 | seekingalpha.comBig Pharma's 5 Hottest Biotech Hunting Grounds: Meet the Category LeadersMay 14, 2026 | 247wallst.comLantheus (NASDAQ:LNTH) Receives Buy Rating from Truist FinancialMay 11, 2026 | marketbeat.comLantheus (NASDAQ:LNTH) Issues Quarterly Earnings ResultsMay 9, 2026 | marketbeat.comLantheus (NASDAQ:LNTH) Cut to "Buy" at Wall Street ZenMay 9, 2026 | marketbeat.comLNTH: Lantheus Reports 1Q:26 Financial and Operational ResultsMay 8, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHRMY, IMVT, KYMR, and LNTH Company DescriptionsHarmony Biosciences NASDAQ:HRMY$32.20 -0.76 (-2.31%) Closing price 04:00 PM EasternExtended Trading$31.96 -0.24 (-0.73%) As of 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.Immunovant NASDAQ:IMVT$31.11 -1.56 (-4.78%) Closing price 04:00 PM EasternExtended Trading$30.58 -0.53 (-1.69%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.Kymera Therapeutics NASDAQ:KYMR$74.13 -0.48 (-0.64%) Closing price 04:00 PM EasternExtended Trading$74.16 +0.03 (+0.03%) As of 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Lantheus NASDAQ:LNTH$100.98 -1.84 (-1.79%) Closing price 04:00 PM EasternExtended Trading$99.83 -1.15 (-1.14%) As of 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
